Neogap Therapeutics, a biotech company focused on developing personalized cancer immunotherapy, announced today the appointment of Dr. Hanjing Xie as its new Chief Medical Officer (CMO), starting on 21 March. Dr. Xie will oversee Neogap's clinical development programs and pipeline and provide medical oversight for the company's first-in-human study. Dr. Xie is a highly experienced associate professor and senior consultant in oncology with diverse expertise from the pharmaceutical industry and university hospitals.
Neogap Therapeutics recently received CTA approval for a phase I/IIa clinical trial with its advanced cell therapy pTTL (personalized Tumor Trained Lymphocytes) cell therapy against colorectal cancer. The phase I/IIa trial is expected to begin in the first half of 2023.
Dr. Hanjing Xie has over 25 years of experience in the pharmaceutical industry at companies such as Idogen, Oncopeptides, and Bayer, and from university hospitals and institutes such as the Karolinska University Hospital, the Karolinska Institute, and St. Göran's hospital. She is an associate professor and senior consultant in oncology, holds a Ph.D. in clinical pharmacology, and has board certifications in clinical oncology, internal medicine, and hematology.
“We are thrilled to welcome Dr. Hanjing Xie as our new Chief Medical Officer. With extensive experience in research, clinical development, and patient care, Dr. Xie brings a wealth of expertise to Neogap. Her diverse background in the pharmaceutical industry and academia and specialized training in clinical oncology and hematology makes her highly qualified to lead our cell therapy trial,” says Samuel Svensson, CEO of Neogap.
“As someone who has dedicated my career to finding new ways to fight cancer, I'm excited to join Neogap, a company at the forefront of personalized cancer immunotherapy. Working with the experienced team at Neogap, I look forward to advancing innovative science and helping to increase survival rates for cancer patients by enhancing tumor-specific immune responses,” says Dr. Hanjing Xie.
About Neogap's cell therapy
Neogap's pTTL cell therapy is an immunotherapy that treats solid tumors by training the immune system to recognize and attack cancer cells using specific altered proteins, so-called neoantigens. A neoantigen develops only in the tumor after a genetic mutation and can therefore be identified as foreign by the body's immune system. Neogap uses two technologies to create a personalized treatment for each patient: PIOR® and EpiTCer®. PIOR® selects the most suitable neoantigens for each patient, while EpiTCer® multiplies T cells that recognize the selected neoantigens and attack the cancer cells, leaving healthy tissue untouched. This minimizes the risk of side effects from the treatment.
For more information, please contact:
Samuel Svensson, CEO
Phone: +46 733 54 21 94
Email: [email protected]
About Neogap Therapeutics
Neogap Therapeutics is a Swedish biotechnology company that develops personalized cancer immunotherapy using the patient's cells. The therapy is based on the company's two technologies, PIOR® and EpiTCer®. PIOR® is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumor-specific mutations. Then, EpiTCer® is used to multiply T cells that can recognize and attack the selected tumor-specific targets. Neogap is located at the Center for Molecular Medicine at the Karolinska Institute in Stockholm. To learn more about Neogap and its cutting-edge research, please visit the company's website at neogap.se and follow Neogap on LinkedIn.
John Carter has been a content and ‘ghostwriter' for many popular online publications over the years. John is now our chief editor at NewsGrab.